Cagrilintide – 10mg
Original price was: $220.00.$150.00Current price is: $150.00.
Cagrilintide is an analog of amylin, developed for research on satiety regulation and energy homeostasis via the amylin receptor pathway.
It is commonly studied for its effects on gastric emptying, appetite modulation, and weight-related signaling cascades in metabolic research models.
LONG-ACTING AMYLIN ANALOGUE
A New Pathway for Satiety and Metabolic Research
Cagrilintide is a long-acting acylated amylin analogue designed to activate central amylin receptors — a distinct satiety pathway separate from GLP-1. With an extended half-life of approximately 160–195 hours, Cagrilintide enables convenient weekly research protocols while providing sustained receptor engagement for comprehensive metabolic studies.
- Long-acting amylin receptor agonist
- Extended half-life (~160–195 hours) supports weekly protocols
- Distinct satiety pathway from GLP-1 agonists
- Acylated structure for enhanced stability
- High purity for reliable research outcomes
For laboratory research use only. Not for human consumption.
CENTRAL AMYLIN SIGNALING
How Cagrilintide Modulates Appetite and Metabolism
Cagrilintide mimics native amylin — a hormone co-secreted with insulin from pancreatic beta cells. By acting on central amylin receptors in the area postrema and hindbrain, it promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion. This mechanism offers a complementary pathway to GLP-1 agonists for metabolic research.
- Activates area postrema and hindbrain amylin receptors
- Promotes satiation and reduces food intake
- Slows gastric emptying for nutrient timing studies
- Inhibits postprandial glucagon secretion
- Complementary mechanism to GLP-1 pathways
For laboratory research use only. Not for human consumption.
RESEARCH APPLICATIONS
From Satiety Studies to Combination Metabolic Research
Cagrilintide has emerged as a key compound for researchers investigating multi-pathway metabolic interventions. Its distinct mechanism makes it ideal for combination studies with GLP-1 agonists like Semaglutide — exploring synergistic effects on appetite, glucose control, and energy balance that neither pathway achieves alone.
- Satiety and appetite regulation studies
- Combination research with GLP-1 agonists
- Gastric emptying and nutrient absorption modeling
- Glucagon suppression and glycemic research
- Beta-cell function and insulin co-secretion studies
- Long-duration metabolic monitoring protocols
For laboratory research use only. Not for human consumption.
The Science Behind Amylin: Why Cagrilintide Opens New Research Frontiers
Cagrilintide represents a significant advancement in metabolic research tools. As a long-acting amylin analogue, it targets a satiety pathway that operates independently of — and complementary to — the GLP-1 system. This distinction makes it invaluable for researchers exploring multi-receptor approaches to metabolic regulation.
Native amylin is co-secreted with insulin from pancreatic beta cells after meals. It acts centrally to reduce appetite, slow gastric emptying, and suppress glucagon release. Cagrilintide’s acylated structure extends these effects over approximately 160–195 hours — enabling weekly research protocols while maintaining consistent receptor activation.
What makes Cagrilintide particularly compelling is its synergistic potential with GLP-1 agonists. By targeting distinct but complementary pathways, combination approaches may achieve metabolic effects that exceed either mechanism alone. This has made Cagrilintide central to next-generation metabolic combination research.
For research teams investigating satiety mechanisms, glucose homeostasis, or multi-pathway metabolic interventions, Cagrilintide provides access to the amylin system with the pharmacokinetic profile needed for sustained, practical research protocols.
For research use only. Not for human consumption.
SCIENTIFIC LITERATURE
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet. 2021;398(10317):2160-2172.
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes. Lancet. 2023.
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide. Diabetes Obes Metab. 2021.
- Dutta D, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian J Endocrinol Metab. 2024;28(5):436-444.
CERTIFICATE
A detailed summary of the analytical profile, purity, and molecular integrity of the research-grade peptide compound.
Be the first to review “Cagrilintide – 10mg”
Related products
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Reviews
There are no reviews yet.